This product is a derivative of prostacyclin (PGI2) with strong antiplatelet aggregation and vasodilation effects. It is a prostacyclin derivative that can be taken orally, with strong vasodilation and antiplatelet aggregation effects.

Dilate blood vessels, inhibit platelet aggregation; stabilize liver cell membranes and improve liver function

This product is an intravenous alprostadil preparation with lipid microspheres as drug carriers. Due to the encapsulation of lipid microspheres, alprostadil is not easy to be inactivated. In addition, this product has the targeting characteristics of being easily distributed to damaged blood vessels, thereby exerting the effects of this product in dilating blood vessels and inhibiting platelet aggregation.

This product belongs to the class of thiazolidinediones oral antidiabetic drugs, and is a highly selective peroxisome proliferator-activated receptor γ (PPARγ) agonist, which controls blood sugar levels by increasing peripheral and liver insulin sensitivity. Its main mechanism of action is to activate PPARγ nuclear receptors in tissues such as fat, skeletal muscle and liver where insulin acts, thereby regulating the transcription of insulin-responsive genes and controlling the generation, transport and utilization of blood sugar.

Unspecified